参考文献 Tingyu Wang, Xiuhua Sun, Lihua Qiu,et al. The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial. Clin...
[6] MARTÍN M, CHAN A, DIRIX L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)[J/OL]. Annals of Oncology: Official Journal of the European Society for...
5. Yang Liu, et al. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94: 604–616. 6. ZhimingLi, et al. Single-Arm Phase 1b/2 Trial of the PI...
[3]Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial. fromhttps://meetinglibrary.asco.org/record/199952/abs...
7. Zhiming Li, et al. Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.Blood. Volume 138, Supplement 1, 23 November 2021, Page 2483.
clinical trial designThe PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may there...
8. 2020 ASCO abstract 1006: Alpelisib + Fulvestrant in Patients With PIK3CA-Mutated Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC) Previously Treated With Cyclin-Dependent Kinase 4/6 Inhibitor (CDKi) + Aromatase Inhibitor (...
2.Ippen Franziska M,Alvarez-Breckenridge Christopher A,Kuter Benjamin M et al. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in -Mutant Breast Cancer Brain Metastases.[J] .Clin. Cancer Res., 2019, undefined: undefined. ...
[11] Hong, David S., et al. "A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors." Clinical Cancer Research 18.15 (2012): 4173-4182.
11. Nicholas Turner, et al.Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial. 2023 ESMO BC. 187O.